We have located links that may give you full text access.
The effectiveness of the intermediate and therapeutic doses of enoxaparin in COVID-19 patients: A comparative study of factor Xa inhibition.
Acta Haematologica 2022 December 21
BACKGROUND: Management of anticoagulant therapy in COVID-19 patients is a critical role. Low Molecular Weight Heparin (LMWH) thromboprophylaxis is already recommended and anti-Factor Xa (anti-FXa) monitoring has been used to titrate LMWH doses.
METHODS: Through a cross-sectional study, we evaluated anti-FXa activity in patients admitted to ICU, receiving intermediate dose (30, 40, 50mg, subcutaneously (SC), twice daily) or therapeutic dose (1 mg/kg, SC, Q12h) of enoxaparin to find whether the patients of these two groups achieve anti-FXa levels in the accepted thromboprophylaxis range.
RESULTS: The occurrence of DVT was 26% in the therapeutic dose and 17% in the intermediate-dose group. D-dimer values were nearly 3.5-fold higher in those who received a therapeutic-dose of anticoagulants than in those who received intermediate dose thromboprophylaxis. Patients in the therapeutic dose group had significantly higher IL-6 levels (p≤0.001). More than one-third of the patients in the therapeutic dose group (n = 8; 42.18%) and approximately half of the patients in the intermediate-dose group (n = 12; 52.2%) achieved the target range level of anti-FXa. Patients who received therapeutic doses were more likely to have anti-FXa levels above the expected range (47.4 Vs 13% in the intermediate dose group. P<0.05).
CONCLUSION: Therapeutic dose of enoxaparin in critically ill COVID-19 infected patients didn't reduce the incidence of thromboembolic events and on the other hand may predispose these patients to increased risk of bleeding by increased anti-FXa activity above the desired level. Administration of intermediate-dose thromboprophylaxis is suggested to achieve anti-FXa levels in the accepted thromboprophylaxis range.
METHODS: Through a cross-sectional study, we evaluated anti-FXa activity in patients admitted to ICU, receiving intermediate dose (30, 40, 50mg, subcutaneously (SC), twice daily) or therapeutic dose (1 mg/kg, SC, Q12h) of enoxaparin to find whether the patients of these two groups achieve anti-FXa levels in the accepted thromboprophylaxis range.
RESULTS: The occurrence of DVT was 26% in the therapeutic dose and 17% in the intermediate-dose group. D-dimer values were nearly 3.5-fold higher in those who received a therapeutic-dose of anticoagulants than in those who received intermediate dose thromboprophylaxis. Patients in the therapeutic dose group had significantly higher IL-6 levels (p≤0.001). More than one-third of the patients in the therapeutic dose group (n = 8; 42.18%) and approximately half of the patients in the intermediate-dose group (n = 12; 52.2%) achieved the target range level of anti-FXa. Patients who received therapeutic doses were more likely to have anti-FXa levels above the expected range (47.4 Vs 13% in the intermediate dose group. P<0.05).
CONCLUSION: Therapeutic dose of enoxaparin in critically ill COVID-19 infected patients didn't reduce the incidence of thromboembolic events and on the other hand may predispose these patients to increased risk of bleeding by increased anti-FXa activity above the desired level. Administration of intermediate-dose thromboprophylaxis is suggested to achieve anti-FXa levels in the accepted thromboprophylaxis range.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app